Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | GLA | P06280 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | APEX1 | P27695 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845556 | 1.00 | ALDH1A1 (0.77) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL13949272 | 0.90 | ALDH1A1 (0.63) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL30978209 | 0.89 | ALDH1A1 (0.63) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL7285516 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL14991107 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL411110 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL411173 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL441970 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL29763164 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL2282787 | 0.86 | KDM4E (0.58) | ALDH1A1POLBKDM4EHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017081676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | PHARMATWOB (IL) | 2017-05-18 | — | — | WO | claimed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| EP-1004581-B1 | Process for the preparation of thalidomide | CELGENE CORP (US) | 2004-09-22 | — | — | EP | claimed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | claimed |
| US-5463063-A | Preparation of thalidomide; inhibitor of tumor necrosis factor | CELGENE CORPORATION (US) | 1995-10-31 | — | — | US | claimed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | claimed |
| WO-1992014455-A1 | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES | THE ROCKEFELLER UNIVERSITY (US) | 1992-09-03 | — | — | WO | claimed |
| WO-2017081676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | PHARMATWOB (IL) | 2017-05-18 | — | — | WO | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150218126-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | GENERICS [UK] LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20130143923-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | GENERICS [UK] LIMITED (GB) | 2013-06-06 | — | — | US | disclosed |
| CN-103068812-A | Crystalline forms of thalidomide and processes for their preparation | GENERICS UK LTD | 2013-04-24 | — | — | CN | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1004581-B1 | Process for the preparation of thalidomide | CELGENE CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1004581-A3 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143923-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | TNF, UACA, VEGFA | ALDH1A1 2821/4885POLB 2597/4885KDM4E 2791/4885 |
| US-20150218126-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | TNF, UACA, VEGFA | ALDH1A1 2821/4885POLB 2597/4885KDM4E 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.